Figure 3.
Overall survival. Shown is overall survival according to CsA exposure, as defined by CsA21, in patients with AML receiving transplantations using an alemtuzumab-based RIC regimen. Used with permission from Craddock et al.16
Overall survival. Shown is overall survival according to CsA exposure, as defined by CsA21, in patients with AML receiving transplantations using an alemtuzumab-based RIC regimen. Used with permission from Craddock et al.16
